This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ampio Spins A Tale of Curing Blindness

Lower doses of Optina, Clift explained, only work in low-BMI patients. If you use a low dose of Optina in an obese patient, the drug doesn't work.

You'd think higher doses of Optina would work regardless of whether the patient had a low or high BMI. If Optina acted like most drugs, a higher dose would lead to greater benefit (up to a point). That's called a positive dose response.

But not true with Optina, according to Clift's interpretation of the study results. Higher doses of Optina only work in patients with a high BMI. If you give a higher dose of Optina to a skinny patient, the drug stops working.

If BMI is so crucial to the efficacy of Optina, why hasn't Ampio ever mentioned this correlation before? Previous disclosures about the Optina study don't talk about efficacy being dependent on patients' respective BMIs, including the press release issued by Ampio last March.

Clift claims Ampio kept all this BMI stuff top secret because of in-progress patent filings. If the company had made public the fact that Optina's efficacy is linked to patient weight, he adds, Big Pharma companies like Pfizer would have swooped in to steal the intellectual property supporting Optina. [Remember, Optina is just low doses of the cheap, generic steroid danazole.]

Before speaking with Clift, Ampio's spokesperson Rick Giles told me that the company discovered the Optina-BMI link only after the clinical trial was underway and the data were being analyzed.

Clift said Giles was mistaken. "There is nothing mysterious in this effect," says Clift. "There is no conspiracy, we're not trying to lie, cheat or steal."

But it surely sounds as if Ampio is engaging in one of the most egregious examples of retrospective data-mining I've ever come across. If Optina was truly a cure for DME-related blindness, patients' vision should improve. Ampio measured the visual acuity of patients in the Optina trial but Clift refused to disclose the results.

By comparison, Lucentis, marketed by Novartis (NVS - Get Report) and Roche (RHHBY) as a therapy for DME and other related eye diseases, actually helps patients see better. Regeneron Pharmaceuticals (REGN - Get Report) hopes to show the same with its recently approved drug Eylea.

As incredulous as Ampio's Optina spin job appears to be, the company's stock is up 27 cents, or 8%, to $3.47 in late Monday trading. Smart investors know stock prices can be deceiving in the short run, yet there's little in Monday's Optina data to justify having much long-term confidence in the drug's future.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
RHHBY $31.57 0.00%
AMPE $4.21 0.00%
NVS $75.97 0.00%
REGN $376.71 0.00%
AAPL $93.74 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs